Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CryoLife, Inc.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
The market for surgical heart valve replacement devices is projected to steadily decline, as newer, more innovative transcatheter techniques poach customers, according to a new report from Informa’s Meddevicetracker.
After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.
While global vaccine heavyweights Merck & Co, Sanofi and GSK are so far not faring so well to successfully develop a vaccine for COVID-19, smaller players are stepping up. That's especially true for segmented markets such as China.
- Implantable Devices
- Other Names / Subsidiaries
- Cardiogenesis Corporation
- CryoLife Asia Pacific, Pte. Ltd.
- CryoLife Europa Ltd
- CryoLife France, SAS
- JOTEC AG
- JOTEC Cardiovascular SL.
- JOTEC Polska Sp. z o.o.
- JOTEC s.r.l.
- On-X Life Technologies Holdings, Inc.
- Ascyrus Medical LLC